EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation with Clinical Characteristics and Possible Mechanisms

Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Scott R. Goldsmith, Mark A. Fiala, Julie O’Neal, George Souroullas, Wael Toama, Ravi Vij, Mark A. SchroederAbstractBackgroundEZH2 is a histone methyltransferase that suppresses genes involved in cell cycle control. Overexpression of EZH2 has been associated with a poor prognosis in various malignancies. Pawlyn et al. recently reported poor outcomes in patients with multiple myeloma and overexpression of EZH2. In order to validate these findings, we analyzed EZH2 expression and outcomes among patients from the CoMMpass study.MethodsWe extracted clinical, expression and genomic data from Interim Analysis 13 of the MMRF CoMMpass study, which harbors data from over 1000 patients with multiple myeloma. Correlations were drawn between EZH2 expression and common genetic mutations. We analyzed the association of EZH2 overexpression with progression-free (PFS) and overall survival (OS).ResultsThe estimated median PFS for patients with EZH2 overexpression was 20.2 months (95% CI 16.3-25.5) compared to 37.2 months (95% CI 31.5-40.7) for patients without (p
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Luo Huang, Yongzhong Wu, Ying Wang, Yue Xie, Furong Wu, Shujie Li, Zhongguo Liang, Xiaodong ZhuAbstractThe aim of this study is to develop a prognostic nomogram for early stage extranodal NK/T-cell lymphoma, nasal-type (ENKL) treated with high-dose radiotherapy (RT). A total of 81 patients at two cancer centers with stage I to IIE ENKL who received chemotherapy (CT) and high-dose RT were retrospectively analyzed. The 5-year OS rate and PFS were 64.7% and 57.5% respectively for the entire group. The development of the ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur findings indicate that prognostic testing rates were poor, and approximately one-third of high-risk patients (del[17p] and TP53) received chemoimmunotherapy, which is not aligned with current CLL treatment recommendations. This represents an opportunity to educate and alert healthcare professionals about the necessity of prognostic testing to guide optimal CLL treatment decisions. Study registration: NCT02582879 (ClinicalTrials.gov).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Daniella Klebaner, Divya Koura, Dimitrios Tzachanis, Edward D. Ball, Steven Horwitz, Aaron M. GoodmanAbstractHepatosplenic T-cell Lymphoma (HSTCL) is a rare peripheral T-cell lymphoma that disproportionately affects individuals with a clinical history of immunosuppression. It carries a poor prognosis, and due to its rarity, there is no single or well-established treatment.We conducted the largest-to-date individual-level meta-analysis based on literature searches to determine the best induction therapy for HSTCL. We c...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Giulia Gabrielli, Alessandro Broccoli, Cinzia Pellegrini, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We describe the recent developments in this field, with emphasis on the complications of therapy and factors contributing to toxicities, efficacy, and resistance. We also describe the ongoing research in this field and the newer CAR-T cell constructs that are being developed to counter the challenges that have been identified in this field.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Tenalisib (RP6530) is a novel, highly specific dual PI3K δ/γ inhibitor with nano-molar potency. It demonstrated acceptable safety up to 1200 mg BID with no DLTs in patients with relapsed/refractory hematologic malignancies. Consistent clinical response was seen at doses 200 mg and above. Further phase I/II studies are being undertaken to evaluate effica cy across different histologies.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Multiple Myeloma (MM) is a plasma cell neoplasm featuring symptoms of hypercalcemia, renal failure, anemia, and lytic bone lesions that comprises approximately 13% of all hematologic malignancies in the United States.1 Although MM is typically associated with the secretion of clonal immunoglobulin proteins (Ig), in 2 to 3 percent of cases, MM patients present without detectable monoclonal Ig by laboratory testing, a phenomenon known as non-secretory multiple myeloma (NSMM).2 NSMM can be further divided into two subtypes: producer NSMM, in which clonal Ig is synthesized but not secreted, and the extremely rare non-producer ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
AbstractRisk-stratification is an essential management tool in defining prognosis of haematological neoplasms, both from patient and physician perspective. We define a new prognostic term “Dynamic Response Assessment Method(s) (DRAM)” as “method(s) used for re-stratifying disease prognosis at fixed intervals during the treatment course”. The risk stratification is done after a fixed duration of treatment or chemotherapy cycles using sensitive techniques. The information obtai ned then can be used for further therapeutic decisions and prognostication. Currently, there is enough evidence that response...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
The aim of this study is to develop a prognostic nomogram for early stage extranodal NK/T-cell lymphoma, nasal-type (ENKL) treated with high-dose radiotherapy (RT). A total of 81 patients at two cancer centers with stage I to IIE ENKL who received chemotherapy (CT) and high-dose RT were retrospectively analyzed. The 5-year OS rate and PFS were 64.7% and 57.5% respectively for the entire group. The development of the nomogram was based on the Cox proportional hazards model. We have implemented the concordance index (C-index) and performed a calibration curve to determine its predictive and discriminatory capacity and compar...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
informCLL is the first US-based registry of patients with CLL that initiated enrollment after approval of novel-targeted agents. Prognostic/predictive testing rates and CLL treatment selection, with availability of novel agents, in clinical practice has not been previously investigated. Results from this interim analysis demonstrate that prognostic/predictive testing was infrequently used to guide treatment selection, potentially inhibiting beneficial outcomes for patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Cancer & Oncology | Genetics | Leukemia | Lymphoma | Myeloma | Study